Debra Resta

12.2k citations
24 papers · 9.0k indexed · 4 hit papers · h-index 15
  • Hematology top 0.05%
    • Chronic Myeloid Leukemia Treatments 13
    • Hematopoietic Stem Cell Transplantation 6
  • Genetics top 0.05%
    • Chronic Lymphocytic Leukemia Research 13
  • Rheumatology top 0.1%
    • Eosinophilic Disorders and Syndromes 9
  • Oncology top 1%
    • Neutropenia and Cancer Infections 4
    • Hematological disorders and diagnostics 4
    • Mast cells and histamine 2
    • Immune Cell Function and Interaction 2

Debra Resta

24 papers receiving 8.7k citations

Hit Papers

Nilotinib (formerly AMN107), a highly selective BCR-ABL t...540200120262009201710002.0k3.0k

Peers

Debra Resta
Comparison fields: 5 of 116
  • Hematology 6.2k
  • Genetics 4.4k
  • Rheumatology 3.1k
  • Gastroenterology 435
  • Oncology 1.8k
Replace Nicholas Lydon with:
Nicholas Lydon Switzerland
Sayuri Ohno-Jones United States
Junia V. Melo United Kingdom
Renaud Capdeville Switzerland
Michael W. Deininger United States
Susan Branford Australia
Michael J. Mauro United States
Susan O’Brien United States
Stephen G. O’Brien United Kingdom
Ian W. Flinn United States
Debra Resta relative to Nicholas Lydon Switzerland Nicholas Lydon's profile →
Citations per field
00.5×1.5×
Nicholas Lydon · 1×
Citations per year

Countries citing papers authored by Debra Resta

Since Specialization
Citations

This map shows the geographic impact of Debra Resta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debra Resta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debra Resta more than expected).

Fields of papers citing papers by Debra Resta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debra Resta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debra Resta. The network helps show where Debra Resta may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Debra Resta, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Debra Resta Line = papers co-authored together Debra Resta links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 2004371
2 200458
3 200393
4 200315
5 200329
6
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemiabreakdown →
20021517
7
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
200285
8 2002227
9
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lympoblastic leukemia with the philadelphia chromosome
20019
10
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosomebreakdown →
20012070
11
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemiabreakdown →
20013811
12 20001
13
Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.
199626
14
Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers.
199634
15
Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings.
19969
16 19958
17
Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.
19953
18 19957
19 199414
20 199339

About Debra Resta

Debra Resta is a scholar working on Hematology, Genetics and Rheumatology, having authored 24 papers that have together received 9.0k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (13 papers), Chronic Myeloid Leukemia Treatments (13 papers), Eosinophilic Disorders and Syndromes (9 papers), Hematopoietic Stem Cell Transplantation (6 papers), Neutropenia and Cancer Infections (4 papers), Hematological disorders and diagnostics (4 papers), Mast cells and histamine (2 papers) and Immune Cell Function and Interaction (2 papers). The work is most often cited by research in Hematology (6.2k citations), Genetics (4.4k citations) and Rheumatology (3.1k citations). Debra Resta has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include Moshe Talpaz, Brian Druker, Renaud Capdeville, Charles L. Sawyers, Hagop M. Kantarjian, J. Ford, Bin Peng, Nicholas Lydon, Elisabeth Buchdunger and Sayuri Ohno-Jones. Their work appears in journals such as Blood, New England Journal of Medicine, American Journal of Clinical Pathology, Cancer and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026